+38 (095) 926-25-85
Trichocosmetics

Modern approaches to the treatment of alopecia areata in children

INESSA SERBINA
Scientific consultant, TRICHOLOGY INSTITUTE ®

Сербина, И. М. Cовременные подходы к терапии гнездной алопеции у детей  / И. М. Сербина // Міжнар. мед. журн. – 2018. – № 1. – С.68–73.


Alopecia areata (AA) is the most common hair disorder in childhood, and its course is unpredictable. AA may involve the scalp and/or hair at other sites, presenting as isolated patches of non-scarring hair loss or as extensive, rapid, total hair loss [1–3]. Recently the number of children with AA has been rising, mainly with an increasing frequency of severe and torpid forms of the disease [4, 5]. The chronic relapsing course of the dermatosis disturbs the child’s emotional sphere, leads to social maladjustment, and substantially impairs the quality of life of the child and of the relatives [1, 6, 7]. To this day the condition remains terra incognita. The latest discoveries in AA research shed light on its genetic and immune pathogenesis. The mechanisms of the disease are based on cell-mediated local immune reactions associated with T lymphocytes (CD8+ and CD4+) and changes in the cytokine profile, determined by genetic factors and exogenous triggers, which leads to nonspecific autoimmune inflammation against a background of broken immune tolerance of the hair follicle. Genetic studies and analysis of human gene expression have shown the significance of disorders of the NKGD-activating ligand and the natural cytotoxicity receptor NKG2D, and of the JAK-STAT signalling system, for the development of AA [2, 8–11].

Analysis of international standards for the treatment of AA, or guidelines, shows that today there is no universal treatment for AA that guarantees the absence of relapse in the future. None of the AA treatments has recommendation class A (strongly recommended, on the basis of at least one level I or II evidence confirming the efficacy of treatment). At the same time, the prevalence of spontaneous remission and the high heterogeneity of AA make it difficult to assess treatment efficacy [6, 12, 13]. It should be noted that there are even fewer studies of AA in children and, consequently, most of the evidence for the paediatric group of patients is extrapolated from data on its treatment in adults and is characterised by a lower degree of reliability of the evidence base.

The disease poses no direct threat to the body. In almost 50 % of children with AA, spontaneous resumption of hair growth is observed within a year of onset, even without treatment. This fact confirms that watchful waiting can be a justified management approach for young children with mild AA [3, 14].

In extensive disease or a progressive course in a young patient, it is important to discuss the different treatment options with the parents. The impact of the disease on the child’s physical and emotional state should be analysed, including such aspects as self-confidence and relationships with peers. A system of measures to overcome the parents’ anxiety, disappointment, feelings of helplessness and guilt should also be part of a comprehensive approach to treating a child with AA.

When choosing a treatment, it is important to weigh the risk level of the agents prescribed, the severity of the disease and the expected therapeutic effect. Preference should be given to pathogenetic therapy whose efficacy is substantiated according to the principles of evidence-based medicine [1, 13].

Topical steroids, thanks to their simplicity, convenience and painlessness, are first-line therapy in children with AA. Preference is given to high-potency topical corticosteroids, in particular clobetasol propionate 0.05 % lotion, with a subsequent step down to less potent forms, such as mometasone furoate 0.1% lotion or betamethasone valerate for the scalp, which help avoid skin atrophy. In a 24-week study of the efficacy of topical clobetasol propionate 0.05 % in 21 children and 1 % hydrocortisone in 20 children with AA, the following results were obtained: in 17 of the 21 who received the lotion there was at least a 50 % increase in hair growth, versus 7 of 20 participants in the other group [5, 15].

Injections of corticosteroids into the deep dermis and the upper subcutaneous layer of the affected areas are the most common treatment for localised AA in adults, allowing optimal tissue concentrations to be reached with minimal systemic absorption [6, 12, 16]. The efficacy of this method was shown in several uncontrolled studies; one of them resulted in significant improvement in 82 % of patients with localised AA who, over 12 weeks, received intralesional injections of triamcinolone acetonide (administered at 2.5 to 10.0 mg/ml; less than 0.1 ml per 1 sq. cm of affected skin) once a month. The side effects of treatment included pain, atrophy and hypopigmentation. Injections into the eyebrow area may be accompanied by complications such as glaucoma, cataract and occlusion of retinal vessels [1, 5].

Intralesional corticosteroid injections are recommended for children over 10 years of age. This method is limited by fear of injections and pain. One study that examined the efficacy of intralesional triamcinolone acetonide injections in 248 children with AA showed that 160 of them reported 50 % improvement at 12 weeks and 211 at 24 weeks. In that study 32 patients refused treatment because of pain [14, 17, 18]. To reduce pain, the following may be used: smaller-gauge needles (30 G or 32 G), ice, anaesthetic creams.

The use of systemic corticosteroids in adult patients with AA promotes resumption of hair growth [12]. However, the known adverse events of long-term therapy with these drugs, in particular growth retardation, metabolic disturbances, decreased bone mineral density and acne, limit its use in children. This method is recommended in the active stage of AA, characterised by a rapid onset or progressive spread of the pathological process. Such patients are prescribed a course of oral prednisolone 0.5–0.8 mg/kg/day with gradual dose reduction over two months, but not more than three [5, 19].

Systemic corticosteroid pulse therapy is a treatment aimed at stopping the inflammatory process without the characteristic long-term side effects [6, 13]. The lack of a control group and of a uniform dosing protocol in most clinical studies of the efficacy of this method makes comparison and meta-analysis of the results difficult. The efficacy of pulse therapy with intravenous methylprednisolone has been shown in several clinical trials, but the risk of hypokalaemia and cardiac arrhythmia requires careful monitoring of patients.

Pulse therapy with high-dose methylprednisolone in children with multiple patches of AA, alopecia totalis (AT) and alopecia universalis (AU) showed an unsatisfactory long-term result: in 66% of patients, on average after 12 months, hair growth of less than 30 % was recorded. No adverse events were reported in this small series of observations. Another study noted that 24 children with AA received intravenous methylprednisolone at a dose of 8 mg/kg body weight for three consecutive days at monthly intervals for three months. Of these, 38 and 29 % of patients had a complete or partial response, respectively, but in 81 % of the patients who initially noted improvement, AA later relapsed [5, 20–22].

Topical immunosuppressive therapy is indicated for severe forms of AA — multifocal AA, AT and AU in the chronic stage. The sensitisers currently used are diphenylcyclopropenone (DPCP) and squaric acid dibutylester (SADBE) [6]. Although Ames test results for these agents indicate no mutagenic effect, none of them has been approved by the FDA, because their safety profile is not fully established. The essence of the method is the artificial induction of allergic contact dermatitis, of the delayed-type hypersensitivity kind, on the skin of a patient with AA. As a result, T suppressors and macrophages are activated; they modify the immune process in the affected area of skin, which promotes resumption of hair growth. The rate of positive clinical response in adult patients varies from 9 to 87 % [12, 13]; in children it proved comparable: resumption of hair growth was observed in about a third of patients in the paediatric group. The relapse rate recorded in studies in children is 25–90 %, and cases of extensive disease had a worse prognosis. Although since the start of topical immunotherapy in 1983 and up to now no serious long-term consequences have been reported, parents and patients must be given detailed information about the common side effects of topical immunotherapy, in particular irritant contact dermatitis. In severe cases generalised eczema, regional lymphadenopathy or urticarial rash may develop in children. Patients with atopic or seborrhoeic dermatitis are at increased risk of such side effects. Hyper- and hypopigmentation, including vitiligo, may be other possible consequences of the treatment discussed [23, 24].

Minoxidil (2,4-diamino-6-piperidino-pyrimidine-3-oxide) is an agent acting directly on the hair bulbs [1, 16]. When used systemically, the drug has a powerful vasodilating effect. The stimulating action of minoxidil on hair growth is exerted through its sulfated metabolite, which acts as a potassium channel opener. The main key mechanisms known to date work through stimulation of the synthesis of VEGF and prostaglandins, and this effect is dose-dependent. One study compared the efficacy of different concentrations of minoxidil (1 and 5 %) in the treatment of extensive AA: in patients receiving 5% minoxidil, resumption of hair growth was more pronounced. The participants in these studies also included children, although data in the paediatric subgroup were not analysed. Minoxidil acts synergistically with corticosteroids and thereby improves the results of AA treatment. It is used twice a day. A common side effect of minoxidil in children, especially at higher concentrations, is hypertrichosis on the face and neck, irritant contact dermatitis, or worsening of pre-existing seborrhoeic or atopic dermatitis. A fall in blood pressure is also possible in them, especially when it is applied to a large area of hair-bearing surface [25].

Moderate efficacy of topical dithranol (anthralin) was shown in several small studies [5]. The drug is used in children with chronic-stage AA after hair loss has stopped. The action of the substance is presumed to consist in suppressing the local Th1-type immune inflammatory reaction in the hair follicle. Dithranol at a concentration of 0.2–0.5 % is a component of creams or ointments; to achieve a clinical effect, the course of use must last at least three months. The most frequent adverse reactions to the drug are redness, scaling, itching, as well as cervical lymphadenopathy and pigmentary skin disorders [26].

Topical calcineurin inhibitors (TCIs) are used successfully in paediatric patients to treat inflammatory conditions such as atopic dermatitis and vitiligo. The main advantage of TCIs is a reduced need for steroids, so they may be considered a treatment option for lesions on the face or the eyebrows in young children. However, studies confirming the efficacy of TCIs are extremely few [27]. In a recent randomised study that compared the efficacy of intralesional corticosteroid injections, their topical use and TCIs in the treatment of localised AA in 78 adult patients, topical tacrolimus was the least effective of the methods listed [5].

Recently, ever more facts have been appearing about the significance of the new JAK-STAT signalling system (Janus Kinases — Signal Transducer and Activator of Transcription) in the development of a number of autoimmune diseases. The JAK-STAT system, or pathway, consisting of Janus kinase (JAK) and the signal transducer and activator of transcription protein (STAT), transmits information from extracellular polypeptide signals through transmembrane receptors directly to the promoters of target genes in the nucleus, without second messengers [29, 30]. Extracellular signals are transmitted to cytokine receptors. Cytokines, by binding to these receptors, can activate various signal transduction pathways. There are a number of cytokines that work specifically with JAK kinases. Jakinibs, drugs that interrupt the mechanism of action of interleukins on the cell by blocking JAK, have shown efficacy in AA. At present tofacitinib, a JAK 1/3 inhibitor that interrupts the STAT-dependent signalling pathway, is approved by the FDA for the treatment of rheumatoid arthritis [11, 28].

In preclinical studies in mice and trials in humans (15 adult patients with moderate and severe AA) using topical and oral tofacitinib, a significant decrease in the activity of cytotoxic T lymphocytes and of the corresponding interferon profile was recorded, accompanied by resumption of hair growth [31].

Experience with tofacitinib in 13 adolescents aged 12–17 years with AA has been described: significant hair growth was recorded in 9 patients, and the percentage change in the mean SALT score was 61 %. Another study showed that all 8 adolescents with AU who received tofacitinib 5 mg twice a day were diagnosed with improvement, with a mean increase in SALT of 58 % at 6 months. The reported side effects were mild. Despite the small sample size, these studies illustrate the efficacy of systemic tofacitinib for AA in adolescents and once again indicate the need for further studies of this group of drugs [28, 31]. Systemic JAK inhibitors are associated with adverse outcomes, including serious infections in 2–6 % of patients. The use of topical agents of this group may reduce the risk of side effects compared with systemic therapy. To date there are data on an adolescent girl with AU who showed significant hair growth with 0.6 % Ruxolitinib cream. Six children aged 3 to 16 years with various forms of AA who received topical JAK inhibitors are reported. The topical agents included 1 and 2 % Tofacitinib and Ruxolitinib creams. Positive results were noted, which were stable for more than 1 year [31].

In the stepwise therapy of AA in children, adjuvant agents, used successfully with a differentiated approach, are no less important [1, 12]. Given the psycho-emotional disturbances, various sedatives are included in the complex therapy. In AA, zinc and copper preparations are prescribed. Multivitamin complexes, preferably with trace elements, are recommended. The group of irritants includes 10% red pepper tincture, bodyaga (freshwater sponge), fresh garlic juice and others. A nonspecific stimulating effect on hair growth is produced by drugs that improve tissue trophism and microcirculation in the skin. In rapid hair loss, silatranes are a promising group of compounds.

Cosmetic correction of the areas lacking hair is of no small importance for achieving psychological comfort. The non-surgical replacement method is a set of cosmetic procedures using a hair system, which provides complete restoration of the lost hair volume [1, 12].

For a patient with AA, adult or child, and for the relatives, psychological support from the doctor, the family and society is very important [7]. In that case the patient will not feel left alone with their problems and will learn to cope adequately with a disease that often becomes chronic. It is important to obtain qualified psychological support and reliable information about the disease itself, to communicate with people who face a similar problem, and to understand that one is not alone in one’s illness.

Thus, today there is still no universal treatment for AA in paediatric practice that guarantees the absence of relapse in the future. Pathogenetic therapy of AA uses glucocorticosteroids, topical immunotherapy, dithranol and minoxidil. Developing treatment “strategies of the future” requires knowledge and understanding of the fine mechanisms of AA pathogenesis, which are based on disturbed cell signalling. The main directions of targeted action in AA are deactivation of T cells and modification of cytokine reactions. Further study of the efficacy and safety of oral and topical JAK kinase inhibitors in AA in children is promising; they prevent the production of cytokines (IFNγ, IL-2 and IL-15, etc.) and potentially reduce the accumulation of CD8+/NKG2D+ T cells. The development of complications and severe side effects, and the insufficient study of the efficacy and safety of individual agents, limit the possibility of wide use of the broad range of therapeutic interventions and determine specialists’ interest in searching for new options in treating the disease.


References

1. Практическая дерматология: учеб. пособ. для врачей- интернов и врачей-слушателей заведений (факультетов) последипломного образования / Л. А. Болотная [и др.]; под общ. ред. Л. А. Болотной.— Харьков: С.А. М., 2015.— 278 с.

2. Alopecia areata update: part I. Clinical picture, histopthology, and pathogenesis / A. Alkhalifah, A. Alsantali, E. Wang [et al.] // J. Am. Acad. Dermatol.— 2010.— Vol. 62, Iss. 2.— P. 177–188.

3. Nanda A. Alopecia areata in children: a clinical profile / A. Nanda, A. S. Al-Fouzan, F. Al-Hasawi // Pediatr. Dermatol.— 2002.— Vol. 19, Iss. 6.— P. 482–485.

4. Tan E. A clinical study of childhood alopecia areata in Singapore / E. Tan, E. K. Tay, Y. C. Giam // Pediatr. Dermatol.— 2002.— Vol. 19.— P. 298–301.

5. Wang E. Current Treatment Strategies in Pediatric Alopecia Areata / E. Wang, J. Lee, M. Tang // Indian J. Dermatol.— 2012.— Vol. 57 (6).— P. 459–465.

6. Alopecia areata update: part II. Treatment / A. Alkhalifah, A. Alsantali, E. Wang [et al.] // J. Am. Acad. Dermatol.— 2010.— Vol. 62, Iss. 2.— P. 191–202.

7. Psychiatric symptomatology and healthrelated qual ity of life in children and adolescents with alopecia areata / Ö. Bilgiç, A. Bilgiç, K. Bahal [et al.] // J. Eur. Acad. Dermatol. Venereol.— 2014.— Vol. 28, Iss. 11.— P. 1463–1468.

8. Genome-wide metaanalysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci / R. C. Betz, L. Petukhova, S. Ripke [et al.] // Nat. Comm.— 2015.— Vol. 6.— P. 5966.

9. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity / L. Petukhova, M. Duvic, M. Hordinsky [et al.] // Nature.— 2010.— Vol. 466, Iss. 7302.— P. 113–117.

10. Paus R. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives / R. Paus, M. Bertolini // J. Dermatol. Invest. Proc.— 2013.— Vol. 1691.— P. S25–S27.

11. Wang E. The Changing Landscape of Alopecia Areata: The Translational Landscape / E. Wang, A. Christiano // Advances in Therapy.— 2017.— Vol. 34, Iss. 7.— P. 1586–1593.

12. Сербина И. М. Гнездная алопеция: лечение и перспективы новых исследований / И. М. Сер- 72 Дерматовенерологія www.imj.kh.ua бина // Клінічна імунологія. Алергологія. Інфекто- логія.— 2012.— No 1.— С. 64–67.

13. Hordinsky M. Alopecia areata: an evidence-based treatment update / M. Hordinsky, A. Donati // Am. J. of Clin. Dermatology.— 2014.— Vol. 15.— P. 231–246.

14. Treatment of alopecia areata in the United States: a retrospective cross-sectional study / M. E. Farhangian, A. J. McMichael, K. E. Huang, S. R. Feldman // J. Drugs Dermatol.— 2015.— Vol. 14, Iss. 9.— P. 1012–1014.

15. Clobetasol propionate, 0.05 %, vs hydrocortisone, 1 %, for alopecia areata in children: a randomized clinical trial / P. Lenane, C. Macarthur, P. C. Parkin [et al.] // JAMA Dermatol.— 2014.— Vol. 150, Iss. 1.— P. 47–50.

16. Gilhar A. Alopecia areata / A. Gilhar, A. Etzioni, R. Paus // N. Engl. J. Med.— 2012.— Vol. 366, Iss. 16.— P. 1515–1525.

17. Chang K. H. Treatment of severe alopecia areata with intralesional steroid injections / K. H. Chang, S. Rojhirunsakool, L. J. Goldberg // J. Drugs Dermatol.— 2009.— Vol. 8, Iss. 10.— P. 909–912.

18. Interventions for alopecia areata / F. M. Delamere, M. J. Sladden, H. M. Dobbins, J. Leonardi- Bee // Cochrane Database Syst. Rev.— 2008.— Vol. 2.— P. CD004413.

19. Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a longterm follow- up study / J. Lalosevic, M. Gajic-Veljic, B. Bonaci- Nikolic, M. Nikolic // Dermatol. Ther.— 2015.— Vol. 28, Iss. 5.— P. 309–317.

20. High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata / A. Smith, R. M. Trueb, M. Theiler [et al.] // Pediatr. Dermatol.— 2015.— Vol. 32, Iss. 4.— P. 481–487.

21. Poor long term outcome of severe alopecia areata in children treated with high dose pulse corticosteroid therapy / T. Hubiche, C. Léauté-Labrèze, A. Taïeb, F. Boralevi // Br. J. Dermatol.— 2008.— Vol. 158, Iss. 5.— P. 1136–1137.

22. Pulse corticosteroid therapy for alopecia areata in children: a retrospective study / R. Friedland, R. Tal, M. Lapidoth [et al.] // Dermatology.— 2013.— Vol. 227, Iss. 1.— P. 37–44.

23. Efficacy and safety of diphenolcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series / M. Durdu, D. Ozcan, M. Baba, D. Seckin // J. Am. Acad. Dermatol.— 2015.— Vol. 72, Iss. 4.— P. 640–650.

24. Salsberg J. M. The safety and efficacy of diphencyprone for the treatment of alopecia areata in children / J. M. Salsberg, J. Donovan // Arch. Dermatol.— 2012.— Vol. 148, Iss. 9.— P. 1084–1085.

25. Herskovitz I. Minoxidil induced hypertrichosis in a 2 year-old child / I. Herskovitz, J. Freedman, A. Tosti // F1000Research.— 2013.— Vol. 2.— P. 226.

26. Özdemir M. Bilateral half-head comparison of 1 % anthralin ointment in children with alopecia areata / M. Özdemir, A. Balevi // Pediatr. Dermatol.— 2017.— Vol. 34, No 2.— P. 128–132.

27. Price V. H. Topical tacrolimus in alopecia areata / V. H. Price, A. Willey, B. K. Chen // J. Am. Acad. Dermatol.— 2005.— Vol. 52, Iss. 1.— P. 138–139.

28. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients / L. Y. Liu, B. G. Craiglow, F. Dai, B. A. King // J. Am. Acad. Dermatol.— 2017.— Vol. 76, Iss. 1.— P. 22–28.

29. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib / A. Jabbari, Z. Dai, L. Xing [et al.] // EBioMedicine.— 2015.— Vol. 2, No 4.— P. 351–355.

30. Randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis / W. C. Ports, S. Khan, S. Lan [et al.] // Br. J. Dermatol.— 2013.— Vol. 169, Iss. 1.— P. 137–145.

31. Craiglow B. G. Tofacitinib for the treatment of alopecia areata and variants in adolescents / B. G. Craiglow, L. Liu, B. King // J. Am. Acad. Dermatol.— 2017.— Vol. 76.— P. 29–32.

Diagnosis and treatment at the Institute

Get a consultation